

## Board Resignation

**MINNEAPOLIS, United States and BRISBANE, Australia 15 December 2025: Anteris Technologies Global Corp. (Anteris or the Company)** (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announces on December 13, 2025 (US ET) / December 14, 2025 (AEST), Mr. Stephen Denaro resigned from the Board of Directors (the “Board”) of Anteris Technologies Global Corp. (the “Company”) and as a Class II director with immediate effect. The resignation from the Board was not due to any disagreement with the Company or its management with respect to any matter relating to the Company’s operations, policies or practices.

Mr. Denaro will continue to serve as the corporate secretary of Anteris Technologies Pty Ltd (“ATPL”) and as a member of the Board of Directors of ATPL and the Company’s other Australian subsidiaries.

The Board thanks Steve for his service.

**ENDS**

### About Anteris

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.

Anteris’ lead product, the DurAVR<sup>®</sup> Transcatheter Heart Valve (**THV**), was designed in collaboration with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR<sup>®</sup> THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR<sup>®</sup> THV is made using a single piece of molded ADAPT<sup>®</sup> tissue, Anteris’ patented anti-calcification tissue technology. ADAPT<sup>®</sup> tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR<sup>®</sup> THV System is comprised of the DurAVR<sup>®</sup> valve, the ADAPT<sup>®</sup> tissue, and the balloon-expandable ComASUR<sup>®</sup> Delivery System.

### Authorisation and Additional information

This announcement was authorised for release on the ASX by the Board of Directors.



**For more information:**

**Investor Relations**

investors@anteristech.com

Debbie Ormsby

Anteris Technologies Global Corp.

+61 1300 550 310 | +61 7 3152 3200

**Investor Relations (US)**

mchatterjee@bplifescience.com

Malini Chatterjee, Ph.D.

Blueprint Life Science Group

+1 917 330 4269

Website [www.anteristech.com](http://www.anteristech.com)

X [@AnterisTech](https://twitter.com/AnterisTech)

LinkedIn <https://www.linkedin.com/company/anteristech>

